Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 7Unknown 4Withdrawn 2Terminated 1Suspended 1Active not recruiting 1

Sponsor Class

OTHER 2NIH 2

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4Other hematologic neoplasm 2Dermatologic 1

Conditions

Lymphoma, Large B-Cell, Diffuse 26Lymphoma 24Precursor Cell Lymphoblastic Leukemia-Lymphoma 19Leukemia 11Neuroblastoma 10Lymphoma, Non-Hodgkin 10Central Nervous System Neoplasms 8Lymphoma, Follicular 6Hodgkin Disease 6Sarcoma 5Retinoblastoma 5Lymphoma, T-Cell, Peripheral 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Mantle-Cell 4Immunoblastic Lymphadenopathy 4Wilms Tumor 3Oligodendroglioma 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Large-Cell, Anaplastic 3Kidney Neoplasms 3Burkitt Lymphoma 3Astrocytoma 3Recurrence 2Neuroectodermal Tumors, Primitive, Peripheral 2Neoplasms, Plasma Cell 2Neoplasms 2Multiple Myeloma 2Leukemia, T-Cell 2Leukemia, Biphenotypic, Acute 2Enteropathy-Associated T-Cell Lymphoma 2

Interventions

Cyclophosphamide 7Doxorubicin 5Vincristine 4fludarabine phosphate 3Gemcitabine 3Alemtuzumab 3Psychiatric Rehabilitation 2Prednisone 2Prednisolone 2Mycophenolic Acid 2Methylprednisolone 2Flow Cytometry 2Cyclosporine 2Cisplatin 2Antilymphocyte Serum 2spartalizumab 1sargramostim 1romidepsin 1prednylidene 1pirarubicin 1motesanib diphosphate 1etoposide phosphate 1Therapeutics 1Thalidomide 1Sensitivity and Specificity 1Rituximab 1Polymerase Chain Reaction 1Pharmacogenomic Testing 1Peripheral Blood Stem Cell Transplantation 1Methotrexate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Unknown × Immunoblastic Lymphadenopathy × Vincristine × Clear all
NCT01719835 2018-03-15

CHEMO-T

Royal Marsden NHS Foundation Trust

Phase 2 Unknown
87 enrolled
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic, Enteropathy-Associated T-Cell Lymphoma

NCT01746992 2017-11-14

CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma

Ruijin Hospital

Phase 4 Unknown
200 enrolled
DermatologicLymphoid

Subcutaneous panniculitis-like T-cell lymphoma, Immunoblastic Lymphadenopathy, Enteropathy-Associated T-Cell Lymphoma

NCT00363090 2013-09-20

Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV T-Cell Non-Hodgkin's Lymphoma

National Cancer Institute (NCI)

Phase 1/2 Unknown
84 enrolled
LymphoidOther hematologic neoplasm

Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT00562068 2013-08-26

Alemtuzumab and Combination Chemotherapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Peripheral T-Cell Lymphoma

National Cancer Institute (NCI)

Phase 1 Unknown
30 enrolled
LymphoidOther hematologic neoplasm

Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡